SBC Medical Group Holdings Sees Q3 Revenue Stabilization and Operating Profit Growth Amidst Near-Term Challenges; Buy-Extended Rating Maintained with $9.00 Price Target.

Emerging Growth Research has reconfirmed its Buy-Extended rating and $9.00 price target for SBC Medical Group Holdings, citing stabilization in Q3:25 revenue and operating profit, a strong cash position, and growth prospects beginning in 2026. The Company added 34 new clinics year-over-year and grew annual customer visits to 6.5 million, with a 72% repeat rate. Management expects revenue to resume its historical +10% to +15% CAGR in 2026.